BridgeBio Pharma (BBIO) Equity Income (2018 - 2026)
BridgeBio Pharma recorded quarterly Equity Income of -$18.3 million in Q1 2026, up 13.06% quarter-over-quarter from -$21.0 million in Q4 2025, and down 17.53% year-over-year from -$22.2 million in Q1 2025.
BridgeBio Pharma's Equity Income history runs 5 years deep, the most recent figure standing at -$18.3 million for Q1 2026.
- In Q1 2026, Equity Income fell 17.53% year-over-year to -$18.3 million; the TTM figure through Mar 2026 stood at -$75.3 million (down 95.45% YoY), while the FY2025 annual figure was -$72.6 million, down 132.84% from the prior year.
- Equity Income came in at -$18.3 million for Q1 2026 at BridgeBio Pharma, up from -$21.0 million in the prior quarter.
- In the past five years, Equity Income ranged from a high of -$6.6 million in Q3 2024 to a low of -$21.0 million in Q4 2025.
- A 3-year average of -$14.2 million and a median of -$15.7 million in 2025 frame the typical range for Equity Income.
- Across the five-year window, Equity Income plunged 154.75% in 2025 and fell 17.53% in 2026, its largest moves.
- BridgeBio Pharma's Equity Income stood at -$8.5 million in 2024, then plunged by 147.4% to -$21.0 million in 2025, then advanced by 13.06% to -$18.3 million in 2026.
- According to Business Quant data, Equity Income over the past three periods registered -$18.3 million, -$21.0 million, and -$15.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 235,807.00 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | BridgeBio Pharma | 12.91 Bn | 11.98 Bn | 184.58 Mn | -18.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -18.28 Mn |
| Dec 31, 2025 | -21.03 Mn |
| Sep 30, 2025 | -15.83 Mn |
| Jun 30, 2025 | -20.19 Mn |
| Mar 31, 2025 | -15.56 Mn |
| Dec 31, 2024 | -8.50 Mn |
| Sep 30, 2024 | -6.56 Mn |
| Jun 30, 2024 | -7.93 Mn |
| Dec 31, 2019 | -4.73 Mn |
| Sep 30, 2019 | -6.59 Mn |
| Jun 30, 2019 | -4.96 Mn |
| Mar 31, 2019 | -4.60 Mn |
| Dec 31, 2018 | 300,000.00 |